Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05888493 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT05888493 · ClinicalTrials.gov record · last posted 2026-04-17

A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma

Study acronym: LEDA
StatusActive, Not Recruiting
PhasePhase 3
Started2023-10-02
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
This trial will compare tisagenlecleucel to standard of care in adult participants with relapsed or refractory (r/r) follicular lymphoma.

Amendment record 28 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 28 times since 2023-05-24; most recent amendment 2026-04-14. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2026-02-13
Status change Recruiting→Active, Not Recruitingv25
2023-08-17
Status change Not Yet Recruiting→Recruitingv1
Trial Details
NCT Number NCT05888493
Lead Sponsor Novartis Pharmaceuticals
Conditions Follicular Lymphoma (FL)
Enrollment 109 participants
Start Date 2023-10-02
Primary Completion 2028-07-25 (estimated)
Study Completion 2031-02-20 (estimated)
Updated on ClinicalTrials.gov 2026-04-17